Syringolin A, a New Plant Elicitor from the Phytopathogenic Bacterium Pseudomonas Syringae Pv. Syringae, Inhibits the Proliferation of Neuroblastoma and Ovarian Cancer Cells and Induces Apoptosis

Overview

Journal Cell Prolif

Date 2006 Nov 18

PMID 17109642

Citations 14

Authors

C S Coleman

J P Rocetes

D J Park

C J Wallick

B J Warn-Cramer

K Michel

R Dudler

A S Bachmann

Affiliations

Soon will be listed here.

Abstract

Syringolin A is a new plant elicitor produced by the plant pathogen Pseudomonas syringae pv. syringae. The goal of this study was to investigate whether syringolin A exhibits anti-proliferative properties in cancer cells. The treatment of human neuroblastoma (NB) cells (SK-N-SH and LAN-1) and human ovarian cancer cells (SKOV3) with syringolin A (0-100 microm) inhibited cell proliferation in a dose-dependent manner. The IC(50) (50% inhibition) for each cell line ranged between 20 microm and 25 microm. In SK-N-SH cells, the treatment with 20 microm syringolin A led to a rapid (24 h) increase of the apoptosis-associated tumour suppressor protein p53. In addition, we found that the treatment of SK-N-SH cells caused severe morphological changes after 48 h such as rounding of cells and loss of adherence, both conditions observed during apoptosis. The induction of apoptosis by syringolin A was confirmed by both poly (ADP-ribose) polymerase (PARP) cleavage and annexin V assay. Taken together, we show for the first time that the natural product syringolin A exhibits anti-proliferative activity and induces apoptosis. Syringolin A and structurally modified syringolin A derivatives may serve as new lead compounds for the development of novel anticancer drugs.

Citing Articles

Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics.

Mir R, Ahad Mir P, Uppal J, Chawla A, Patel M, Bardakci F Metabolites. 2023; 13(4).

PMID: 37110167 PMC: 10142660. DOI: 10.3390/metabo13040509.

Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.

Schultz C, Gruhlke M, Slusarenko A, Bachmann A J Nat Prod. 2020; 83(8):2518-2527.

PMID: 32786875 PMC: 9162488. DOI: 10.1021/acs.jnatprod.0c00613.

Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.

Pierce M, Robinson R, Ibarra-Rivera T, Pirrung M, Dolloff N, Bachmann A Leuk Res. 2019; 88:106271.

PMID: 31778912 PMC: 6937391. DOI: 10.1016/j.leukres.2019.106271.

Heterologous expression and antitumor activity analysis of syringolin from Pseudomonas syringae pv. syringae B728a.

Huang F, Tang J, He L, Ding X, Huang S, Zhang Y Microb Cell Fact. 2018; 17(1):31.

PMID: 29482589 PMC: 6389232. DOI: 10.1186/s12934-018-0859-1.

Immunoproteasome inhibition and bioactivity of thiasyrbactins.

Bakas N, Schultz C, Yco L, Roberts C, Chang C, Bachmann A Bioorg Med Chem. 2017; 26(2):401-412.

PMID: 29269255 PMC: 5920785. DOI: 10.1016/j.bmc.2017.11.048.

References

Fo C, Coleman C, Wallick C, Vine A, Bachmann A . Genomic organization, expression profile, and characterization of the new protein PRA1 domain family, member 2 (PRAF2). Gene. 2006; 371(1):154-65. DOI: 10.1016/j.gene.2005.12.009. View

Amrein H, Makart S, Granado J, Shakya R, Schneider-Pokorny J, Dudler R . Functional analysis of genes involved in the synthesis of syringolin A by Pseudomonas syringae pv. syringae B301 D-R. Mol Plant Microbe Interact. 2004; 17(1):90-7. DOI: 10.1094/MPMI.2004.17.1.90. View

McKenzie P, Guichard S, Middlemas D, Ashmun R, Danks M, Harris L . Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res. 2000; 5(12):4199-207. View

Wang H, Altomare D, Skele K, Poulikakos P, Kuhajda F, Di Cristofano A . Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene. 2005; 24(22):3574-82. DOI: 10.1038/sj.onc.1208463. View

Harris S, Levine A . The p53 pathway: positive and negative feedback loops. Oncogene. 2005; 24(17):2899-908. DOI: 10.1038/sj.onc.1208615. View

Tweddle D, Malcolm A, Cole M, Pearson A, Lunec J . p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol. 2001; 158(6):2067-77. PMC: 1892004. DOI: 10.1016/S0002-9440(10)64678-0. View

Li X, Darzynkiewicz Z . Cleavage of Poly(ADP-ribose) polymerase measured in situ in individual cells: relationship to DNA fragmentation and cell cycle position during apoptosis. Exp Cell Res. 2000; 255(1):125-32. DOI: 10.1006/excr.1999.4796. View

Derry W, Wilson L, Khan I, Luduena R, Jordan M . Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry. 1997; 36(12):3554-62. DOI: 10.1021/bi962724m. View

Bachmann A, Xu R, Ratnapala L, Patil S . Inhibitory effects of phaseolotoxin on proliferation of leukemia cells HL-60, K-562 and L1210 and pancreatic cells RIN-m5F. Leuk Res. 2003; 28(3):301-6. DOI: 10.1016/j.leukres.2003.07.002. View

10.

Heiligtag S, Bredehorst R, David K . Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ. 2002; 9(9):1017-25. DOI: 10.1038/sj.cdd.4401055. View

11.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

12.

Mayer A, Gustafson K . Marine pharmacology in 2001-2: antitumour and cytotoxic compounds. Eur J Cancer. 2004; 40(18):2676-704. DOI: 10.1016/j.ejca.2004.09.005. View

13.

MULLINS D, Alleva D, Burger C, Elgert K . Taxol, a microtubule-stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production. Immunopharmacology. 1997; 37(1):63-73. DOI: 10.1016/s0162-3109(97)00004-0. View

14.

Fulda S, Debatin K . Apoptosis pathways in neuroblastoma therapy. Cancer Lett. 2003; 197(1-2):131-5. DOI: 10.1016/s0304-3835(03)00091-0. View

15.

El Sayed K . Natural products as angiogenesis modulators. Mini Rev Med Chem. 2005; 5(11):971-93. DOI: 10.2174/138955705774575291. View

16.

Goldberg G, Lau A . Dynamics of connexin43 phosphorylation in pp60v-src-transformed cells. Biochem J. 1993; 295 ( Pt 3):735-42. PMC: 1134622. DOI: 10.1042/bj2950735. View

17.

Tweddle D, Pearson A, Haber M, Norris M, Xue C, Flemming C . The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003; 197(1-2):93-8. DOI: 10.1016/s0304-3835(03)00088-0. View

18.

Hamblin T . Natural products and the treatment of leukemia. Leuk Res. 2005; 30(6):649-50. DOI: 10.1016/j.leukres.2005.10.023. View

19.

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

20.

Wallick C, Gamper I, Thorne M, Feith D, Takasaki K, Wilson S . Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene. 2005; 24(36):5606-18. DOI: 10.1038/sj.onc.1208808. View